As Covid-re­lat­ed chal­lenges weigh on pa­tient re­cruit­ment, biotech scraps PhI­Ib/III Parkin­son's pro­gram

More than two years af­ter lit­tle Swiss biotech Ad­dex Ther­a­peu­tics post­poned a Phase IIb/III tri­al in­def­i­nite­ly due to the then-nascent Covid-19 pan­dem­ic, it’s throw­ing in the tow­el.

As with two years ago, Covid was to blame.

“We took this de­ci­sion be­cause it was not fea­si­ble to con­tin­ue the study at such a slow re­cruit­ment rate in the cur­rent en­vi­ron­ment. I’d like to em­pha­size that it was not dipraglu­rant re­lat­ed and we con­tin­ue to be­lieve in the po­ten­tial of this com­pound as a treat­ment for PD-LID,” CEO Tim Dy­er said in a state­ment.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER